19-21 April, Liverpool
| Chimeric Antigen Receptor T-Cell Therapy.. | Rachel Fletcher .. | Dr. Arief Gunawan. Email: arie.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Clinical Utility of Pre-ASCT Bone Marrow.. | Jemma Larham .. | Janine QASIM, Grant VALLANCE, .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| MGUS monitoring >90 years old- age is ju.. | Lowri Morgan .. | Presenting Author: Dr Susannah.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| UK Nurses´ and Pharmacists´ Preferences .. | Catherine Loughran .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Belantamab mafodotin, pomalidomide and d.. | Adil Merchant .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Belantamab mafodotin, bortezomib and dex.. | Adil Merchant .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Transplant decision-making in newly diag.. | Neil Rabin .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Integrating Geriatric Expertise into Mye.. | Joanna Preston .. | F. Willis2, Y. Reyal2, T. Vato.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Dexamethasone dosing in daratumumab-lena.. | Peter Thom .. | Sudarshan Gurung.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Safe transition to outpatient bispecific.. | Victor Ling .. | Ling V, Tudor I, Lewis V, Food.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Cost effectiveness analysis of Denosumab.. | Micheal Brennan .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Prolonged elranatamab treatment interrup.. | Emma Searle .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Treatment Priorities of Patients With Re.. | Rakesh Popat .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Cognitive frailty, an Under-recognised A.. | Sumayyah Patel .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Earlier Use of Ciltacabtagene Autoleucel.. | Niall Gilding .. | Samir Parekh, Katherine Li, Ni.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Daratumumab in transplant-eligible newly.. | Fredrik Schjesvold .. | Philippe Moreau, Pieter Sonnev.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Daratumumab Monotherapy Versus Active Mo.. | Jindriska Lindsay .. | Peter M Voorhees, Meletios A D.. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| REALiTEC-2: International Observational .. | Rakesh Popat .. | Katarina Uttervall, K. Martin .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Daratumumab-Bortezomib-Lenalidomide-Dexa.. | SUPRATIK Basu .. | Saad Z Usmani, Thierry Facon, .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
| Safety and efficacy of AZD0120 BCMA/CD19.. | Simon Rule .. | .. | 03. Plasma Cell Dyscrasias (Myeloma, Amy.. | - - | |
Thunderstorm-related asthma in patients sensitised to olea europaea pollen: twenty emergency department visits for asthmatic symptoms in one single day Losappio, Laura1; Heffler, Enrico2; Falco, Antonio1; Contento, Francesco1; Cannito, Cosimo1; Rolla, Giovanni2 1"Dimiccoli" Hospital, Emergency Department, Barletta, Italy; 2University of Torino - AO Mauriziano "Umberto I", Allergy and Clinical Immunology, Torino, Italy
Background: Associations between thunderstorm and asthma morbidity have been reported in several countries. Common to all epidemics of thunderstorm-related asthma is a significant increase in atmospheric allergen load during and immediately after a thunderstorm. Sensitization to Alternaria species or to grass and parietaria pollens has been suggested to play a key role in thunderstorm-related asthma. The only reported event of thunderstorm-related asthma in Mediterranean area was attributed to sensitization to parietaria pollen.
Method: here we describe a series of 20 patients who presented to Emergency Department in Barletta (94,000 inhabitants), Puglia (Italy) for sudden and severe asthmatic symptoms between May 27th and 28th 2010 (from15:36 to 5:02), immediately after a violent thunderstorm which occurred following a very hot morning (mean temperature: 29°C). All the patients have been subsequently visited by an allergist and underwent allergological work-up which included skin prick tests and a careful clinical history. Local pollen counts were available.
Result: Between May 10th and June 10th 2010, 86 Emergency Department asthma visits were recorded, 20 of them during the study day. Patients' mean age was 44.25 +/- 18.5 years (range: 9-81), 8/20 females, 2 smokers, 16 with a previous history of known respiratory allergy. Only two patients regularly took anti-asthma drugs. All 20 patients were sensitized to Olea europaea pollen, 7 of whom were monosensitized. Ten patients were sensitized to grass, 7 to parietaria, 5 to compositae, 5 to cypress, 5 to house dust mites, 3 to dog and 1 to cat danders. No patient was sensitized to Alternaria. Mean pollen count was 17 granules/m3 for Olea europaea, 6 granules/m3 for grass pollen.
Conclusion: This is, in our knowledge, the second epidemic of thunderstorm related asthma described in Mediterranean area and the first one in which sensitization to Olea europaea played a key-role. In conclusion, our report indicates that thunderstorm asthma may involve different allergens (not only fungal spores and grass or parietaria pollen) in different geographic areas, depending on the seasonality of thunderstorms and allergenic pollen.